

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2812355

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ISIS PHARMACEUTICALS, INC.	04/09/2010
RECEIVING PARTY DATA	
Name:	REGULUS THERAPEUTICS INC.
Street Address:	1896 RUTHERFORD ROAD
City:	CARLSBAD
State/Country:	CALIFORNIA
Postal Code:	92008
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14168812
CORRESPONDENCE DATA	
Fax Number:	(608)662-1276
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	macheckett@casimirjones.com
Correspondent Name:	REBECCA B. SCARR
Address Line 1:	CASIMIR JONES S.C.
Address Line 2:	2275 DEMING WAY STE, 310
Address Line 4:	MIDDLETON, WISCONSIN 53562
ATTORNEY DOCKET NUMBER:	REGUL-32416/US-4/DIV
NAME OF SUBMITTER:	REBECCA B. SCARR
SIGNATURE:	/Rebecca B. Scarr/
DATE SIGNED:	04/14/2014
Total Attachments: 3	
source=2010-04-12_32416US3DIV_Assign-Isis-Regulus#page1.tif	
source=2010-04-12_32416US3DIV_Assign-Isis-Regulus#page2.tif	
source=2010-04-12_32416US3DIV_Assign-Isis-Regulus#page3.tif	

ASSIGNMENT

WHEREAS, Isis Pharmaceuticals, Inc. a Delaware corporation having its principal office at 1896 Rutherford Road, Carlsbad, California 92008 (hereinafter referred to as the "Assignor") is the assignee of record of the inventions listed in "Table A"; and


WHEREAS, Regulus Therapeutics Inc., a Delaware corporation having its principal office at 1896 Rutherford Road, Carlsbad, California 92008 (hereinafter referred to as the "Assignee") desires to acquire the entire interest in the same;

NOW, THEREFORE, for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor, hereby does assign and transfer unto Assignee, the entire right, title and interest in and to the patents and the applications listed in "Table A" throughout the world, including, without limitation, any letters patent which may issue thereon, and any subsequent application claiming priority to the above-identified application under reissue, reexamination, division, continuation-in-part, extension or continuation thereof and all rights of priority under international conventions arising from said applications; the same for its legal representatives and assigns, as fully and entirely as the same would have been held by Assignor had this assignment and sale not been made;

AND, Assignor hereby binds itself, legal representatives, employees, successors and assigns to properly execute, without further consideration other than in reimbursement of directly related, reasonable expenses, any and all applications, petitions, oaths and assignments or other papers and instruments which may be necessary in order to perfect title in the patents and applications and carry into full force and effect, the sale, assignment, transfer and conveyance hereby made or intended to be made and generally do everything possible to aid Assignee, its legal representatives, successors and assigns, to obtain proper protection for the inventions in all countries throughout the world, including to communicate to Assignee, its representatives or agents, any facts relating to the inventions, the patents or applications, including evidence for purposes of interference, opposition; and execute and deliver, on request, all lawful papers required to make any of the foregoing provisions effective.

Assignor hereby authorizes and requests the issuing authority to record this assignment of the patents and applications in "Table A" and to issue any and all patents on said applications to Assignee, as assignee of the entire interest in such patents.

IN WITNESS WHEREOF, I have executed this Assignment on the date shown below on behalf of Isis Pharmaceuticals, Inc.



Name: B. Lynne Parshall
Title: COO and CFO
Address: Isis Pharmaceuticals, Inc.
1896 Rutherford Road
Carlsbad, California 92008

April 9, 2010
Date

On April 9, 2010 before me, Laura L. Eames, Notary Public, personally appeared **B. Lynne Parshall**, who is proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.





Signature of Notary

Acknowledgement of Assignee

REGULUS THERAPEUTICS Inc.

By: April 9, 2010

Date: 49
XANTHOPOULOS

Kleanthis G. Xanthopoulos, Ph.D.
President and CEO

Table A

Docket Number	Country	Serial Number	Filing Date	Title
REG-0003US.L	United States	60/983,231	10/29/2007	TARGETING MICRORNAS FOR THE TREATMENT OF LIVER CANCER
REG-0003WO	Patent Corporation Treaty	PCT/US2008/081645	10/29/2008	TARGETING MICRORNAS FOR THE TREATMENT OF LIVER CANCER